

## **Cannabis (medical marijuana) treatment for motor and non-motor symptoms of Parkinson disease: an open-label observational study**

Source: [Cannabis \(medical marijuana\) treatment for motor and non-motor symptoms of Parkinson disease: an open-label observational study - PubMed \(nih.gov\)](#)

Itay Lotan 1, Therese A Treves, Yaniv Roditi, Ruth Djaldetti

### Abstract

**Objective:** The use of cannabis as a therapeutic agent for various medical conditions has been well documented. However, clinical trials in patients with Parkinson disease (PD) have yielded conflicting results. The aim of the present open-label observational study was to assess the clinical effect of cannabis on motor and non-motor symptoms of PD.

**Methods:** Twenty-two patients with PD attending the motor disorder clinic of a tertiary medical center in 2011 to 2012 were evaluated at baseline and 30 minutes after smoking cannabis using the following battery: Unified Parkinson Disease Rating Scale, visual analog scale, present pain intensity scale, Short-Form McGill Pain Questionnaire, as well as Medical Cannabis Survey National Drug and Alcohol Research Center Questionnaire.

**Results:** Mean (SD) total score on the motor Unified Parkinson Disease Rating Scale score improved significantly from 33.1 (13.8) at baseline to 23.2 (10.5) after cannabis consumption ( $t = 5.9$ ;  $P < 0.001$ ). Analysis of specific motor symptoms revealed significant improvement after treatment in tremor ( $P < 0.001$ ), rigidity ( $P = 0.004$ ), and bradykinesia ( $P < 0.001$ ).

**Conclusions:** There was also significant improvement of sleep and pain scores. No significant adverse effects of the drug were observed. The study suggests that cannabis might have a place in the therapeutic armamentarium of PD. Larger, controlled studies are needed to verify the results.

### Similar articles

Effect of medical cannabis on thermal quantitative measurements of pain in patients with Parkinson's disease.

Shohet A, Khlebtovsky A, Roizen N, Roditi Y, Djaldetti R.

Eur J Pain. 2017 Mar;21(3):486-493. doi: 10.1002/ejp.942. Epub 2016 Oct 10.

PMID: 27723182

Randomized trial of pallidotomy versus medical therapy for Parkinson's disease.

Vitek JL, Bakay RA, Freeman A, Evatt M, Green J, McDonald W, Haber M, Barnhart H, Wahlay N, Triche S, Mewes K, Chockkan V, Zhang JY, DeLong MR.

Ann Neurol. 2003 May;53(5):558-69. doi: 10.1002/ana.10517.

PMID: 12730989 Clinical Trial.

Progression of motor and nonmotor features of Parkinson's disease and their response to treatment. Vu TC, Nutt JG, Holford NH.

Br J Clin Pharmacol. 2012 Aug;74(2):267-83. doi: 10.1111/j.1365-2125.2012.04192.x.

PMID: 22283961 Free PMC article.

Gender differences in motor and non-motor symptoms among Sardinian patients with Parkinson's disease.

Solla P, Cannas A, Ibba FC, Loi F, Corona M, Orofino G, Marrosu MG, Marrosu F.

J Neurol Sci. 2012 Dec 15;323(1-2):33-9. doi: 10.1016/j.jns.2012.07.026. Epub 2012 Aug 27.

PMID: 22935408

Progression of motor symptoms in Parkinson's disease.

Xia R, Mao ZH.

Neurosci Bull. 2012 Feb;28(1):39-48. doi: 10.1007/s12264-012-1050-z.

PMID: 22233888 Free PMC article. Review.

See all similar articles

Cited by

Impacts of medical and non-medical cannabis on the health of older adults: Findings from a scoping review of the literature.

Wolfe D, Corace K, Butler C, Rice D, Skidmore B, Patel Y, Thayaparan P, Michaud A, Hamel C, Smith A, Garber G, Porath A, Conn D, Willows M, Abramovici H, Thavorn K, Kanji S, Hutton B.

PLoS One. 2023 Feb 17;18(2):e0281826. doi: 10.1371/journal.pone.0281826. eCollection 2023.

PMID: 36800328 Free PMC article. Review.

Cannabidiol-enriched cannabis extraction product in Parkinson's disease: A randomized, double-blind, and placebo-controlled trial in Buriram Hospital.

Kanjanarangsichai A, Mitarnun W, Mitarnun W, Pangwong W, Laoharattanahirun N, Kajornrith W, Junlaor P, Nonghan P, Witthayapirote W, Sangkarom G.

J Neurosci Rural Pract. 2022 Oct-Dec;13(4):663-668. doi: 10.25259/JNRP-2022-6-19. Epub 2022 Oct 22.

PMID: 36743777 Free PMC article.

Therapeutic Molecular Insights into the Active Engagement of Cannabinoids in the Therapy of Parkinson's Disease: A Novel and Futuristic Approach.

Jain V, Behl T, Sehgal A, Singh S, Sharma N, Makeen HA, Albratty M, Meraya AM, Najmi A.

Neurotox Res. 2023 Feb;41(1):85-102. doi: 10.1007/s12640-022-00619-y. Epub 2022 Dec 26.

PMID: 36567416 Review.

Mepirapim, a novel synthetic cannabinoid, induces Parkinson's disease-related behaviors by causing maladaptation of the dopamine system in the brain.

Hur KH, Lee Y, Donio AL, Lee JG, Lee BR, Kim SK, Yoon S, Lee YS, Kim HC, Lee SY, Jang CG.

Arch Toxicol. 2023 Feb;97(2):581-591. doi: 10.1007/s00204-022-03414-y. Epub 2022 Nov 10.

PMID: 36355181